Show simple item record

dc.contributor.authorSergeev, A.en_US
dc.contributor.authorSergeev, A.en_US
dc.contributor.authorPetrishchenko, V.en_US
dc.contributor.authorShishkina, L.en_US
dc.contributor.authorKochneva, G.en_US
dc.contributor.authorZhukov, V.en_US
dc.contributor.authorEvtin, N.en_US
dc.contributor.authorPyankov, O.en_US
dc.contributor.authorSandakhchiyev, L.en_US
dc.contributor.authorAkinfeeva, L.en_US
dc.contributor.authorUdut, V.en_US
dc.contributor.authorSherstoboyev, E.en_US
dc.contributor.authorGoldberg, E.en_US
dc.contributor.authorMelnikov, S.en_US
dc.contributor.authorPodkuiko, V.en_US
dc.contributor.authorMaximov, V.en_US
dc.contributor.editorDmitrii K Lvoven_US
dc.date.accessioned2017-05-03T16:55:44Z
dc.date.available2017-05-03T16:55:44Z
dc.date.issued2004en_US
dc.date.modified2009-04-16T06:53:13Z
dc.identifier.issn05074088en_US
dc.identifier.urihttp://hdl.handle.net/10072/22169
dc.description.abstractThe reactogenicity of the embryonic live recombinant variola and hepatitis B bivaccine as tablets (Revax-BT) as well as its safety and immunogenicity were evaluated in clinical trials made in volunteers who had previously immunized or not with variola vaccine. A preliminary conclusion was made on a lack of side effects and drug safety in primary vaccination and been revaccination with low and high doses. Primary immunization of volunteers and as bivaccination with high doses stimulated the most pronounced immune response to the vaccine virus versus such effect observed in immunization of volunteers with low vaccine doses. Humoral immune response to HBs was observed in 75% of volunteers of both groups after as bivaccination. Such response was most pronounced in examinees immunized with low vaccine doses versus those who received high bivaccine doses. At the same time, no protective levels of humoral immunity response to HBs Ag were observed in volunteers first vaccinated.en_US
dc.description.peerreviewedYesen_US
dc.description.publicationstatusYesen_AU
dc.languageRussianen_US
dc.language.isoen_AU
dc.publisherIzdatel'stvo Meditsinaen_US
dc.publisher.placeRussian Federationen_US
dc.publisher.urihttp://www.ncbi.nlm.nih.gov/pubmed/15529859en_AU
dc.relation.ispartofpagefrom22en_US
dc.relation.ispartofpageto26en_US
dc.relation.ispartofissue5en_US
dc.relation.ispartofjournalVoprosy Virusologiien_US
dc.relation.ispartofvolume49en_US
dc.subject.fieldofresearchcode270304en_US
dc.titleReactogenicity, safety and immunogenicity of a recombinant bivaccine against smallpox and hepatitis B in limited clinical trialsen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.date.issued2004
gro.hasfulltextNo Full Text


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record